Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18558528 | 0.90 | MAPT (0.32) | HCAR2GPR84NR1I2 | |
| SCHEMBL22815352 | 0.84 | CYP1A2 (0.39) | HCAR2GPR84NR1I2HCAR3 | |
| SCHEMBL19362661 | 0.84 | CYP1A2 (0.39) | HCAR2GPR84NR1I2HCAR3 | |
| SCHEMBL22815348 | 0.84 | CYP1A2 (0.39) | HCAR2GPR84NR1I2HCAR3 | |
| SCHEMBL19362615 | 0.79 | HPGD (0.32) | HCAR2GPR84NR1I2 | |
| SCHEMBL19362616 | 0.79 | AURKA (0.33) | HCAR2GPR84NR1I2 | |
| SCHEMBL24688350 | 0.77 | HCAR2 (0.38) | HCAR2GPR84HCAR3 | |
| SCHEMBL24688161 | 0.73 | CHEK1 (0.41) | HCAR2GPR84HCAR3 | |
| SCHEMBL22431886 | 0.71 | NR1I2 (0.36) | GPR84NR1I2LMNADNM1 | |
| SCHEMBL23569869 | 0.71 | NR1I2 (0.36) | GPR84NR1I2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | HCAR2 1050/4885GPR84 695/4885NR1I2 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.